{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:47:45Z","timestamp":1790549265973,"version":"4.1.0"},"reference-count":120,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Bone metastases are frequently the final fate of breast and prostate cancer patients. According to the definition of metastasis as an incurable disease, to date there are no effective treatments for tumor-associated bone metastases and this represents a real challenge for the researchers in the field. The bone is a heterogeneous environment that represents a fertile soil for tumor cells, supporting their growth. Among the different cell types present in the bone, in this review we will focus our attention on the osteoclasts, which are crucial players in the so called \u201cvicious cycle\u201d, a phenomenon triggered by tumor cells eventually leading to both tumor proliferation as well as bone deregulation, thus fueling the development of bone metastasis. The complex network, linking tumor cells to the bone by activating osteoclasts, represents a fruitful target for the treatment of bone metastases. In this review we will describe how tumor cells perturb the bone microenvironment by actively influencing osteoclast formation and activity. Moreover, we will describe the current antiresorptive drugs employed in the treatment of bone metastases as well as new, targeted therapies able to affect both cancer cells and osteoclasts.<\/jats:p>","DOI":"10.3390\/cancers10070218","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T11:02:05Z","timestamp":1530097325000},"page":"218","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["The Osteoclast in Bone Metastasis: Player and Target"],"prefix":"10.3390","volume":"10","author":[{"given":"Antonio","family":"Maurizi","sequence":"first","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rucci","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: Clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following bone recurrence from breast cancer","volume":"77","author":"Coleman","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0889-8588(05)70364-6","article-title":"How is androgen-dependent metastatic prostate cancer best treated?","volume":"10","author":"Robson","year":"1996","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/annonc\/mdg348","article-title":"Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients","volume":"14","author":"Koizumi","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10147-012-0414-8","article-title":"Treatment of bone metastases before the onset of pain","volume":"18","author":"Costa","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: A review","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cncr.11144","article-title":"Bone cancer pain","volume":"97","author":"Clohisy","year":"2003","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of Bone Metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0004563218759371","article-title":"The Bone Remodelling Cycle","volume":"55","author":"Kenkre","year":"2018","journal-title":"Ann. Clin. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1359\/jbmr.2001.16.9.1575","article-title":"Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers","volume":"16","author":"Hauge","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1359\/jbmr.2002.17.1.77","article-title":"The bone lining cell: Its role in cleaning Howship\u2019s lacunae and initiating bone formation","volume":"17","author":"Everts","year":"2002","journal-title":"J. Bone Miner. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Delaisse, J.-M. (2014). The reversal phase of the bone-remodeling cycle: Cellular prerequisites for coupling resorption and formation. Bonekey Rep., 3.","DOI":"10.1038\/bonekey.2014.56"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2741\/1576","article-title":"The role of matrix vesicles in growth plate development and biomineralization","volume":"10","author":"Anderson","year":"2005","journal-title":"Front. Biosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.abb.2014.08.009","article-title":"Reprint of: The Great Beauty of the osteoclast","volume":"561","author":"Cappariello","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V75.1.1.bloodjournal7511","article-title":"Colony-stimulating factor-1 receptor","volume":"75","author":"Sherr","year":"1990","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1073\/pnas.87.12.4828","article-title":"Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (OP\/OP) mouse","volume":"87","author":"Bartocci","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","first-page":"65","article-title":"Osteoclast formation and differentiation: An overview","volume":"59","author":"Soysa","year":"2012","journal-title":"J. Med. Dent. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nakashima, T., and Takayanagi, H. (2011). New regulation mechanisms of osteoclast differentiation. Ann. N. Y. Acad. Sci., 1240.","DOI":"10.1111\/j.1749-6632.2011.06373.x"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","article-title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis","volume":"202","author":"Asagiri","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","article-title":"Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Dev. Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45969","DOI":"10.1074\/jbc.M408795200","article-title":"Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1","volume":"279","author":"Matsumoto","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"35209","DOI":"10.1074\/jbc.M505815200","article-title":"Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis","volume":"280","author":"Kim","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gene.2005.12.012","article-title":"NFATc1 regulation of the human \u03b23 integrin promoter in osteoclast differentiation","volume":"372","author":"Crotti","year":"2006","journal-title":"Gene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI117979","article-title":"The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow","volume":"95","author":"Mbalaviele","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2613.2000.00164.x","article-title":"Osteoclasts and giant cells: Macrophage-macrophage fusion mechanism","volume":"81","author":"Vignery","year":"2000","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2003.12.029","article-title":"ADAM gene expression and regulation during human osteoclast formation","volume":"35","author":"Verrier","year":"2004","journal-title":"Bone"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.20050645","article-title":"DC-STAMP is essential for cell\u2013cell fusion in osteoclasts and foreign body giant cells","volume":"202","author":"Yagi","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/nm1514","article-title":"V-ATPase V0subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation","volume":"12","author":"Lee","year":"2006","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1083\/jcb.99.5.1696","article-title":"Cell-substratum interaction of cultured avian osteoclasts is mediated by specific adhesion structures","volume":"99","author":"Marchisio","year":"1984","journal-title":"J. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/cm.21119","article-title":"Podosomes in adhesion, migration, mechanosensing and matrix remodeling","volume":"70","author":"Schachtner","year":"2013","journal-title":"Cytoskeleton"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18636","DOI":"10.1074\/jbc.272.30.18636","article-title":"Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption","volume":"272","author":"Schlesinger","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/03008208909023879","article-title":"Polarity and membrane transport in osteoclasts","volume":"20","author":"Baron","year":"1989","journal-title":"Connect. Tissue Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/jemt.10371","article-title":"Intracellular membrane trafficking in bone resorbing osteoclasts","volume":"61","author":"Mulari","year":"2003","journal-title":"Microsc. Res. Tech."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hirvonen, M.J., Fagerlund, K., Lakkakorpi, P., V\u00e4\u00e4n\u00e4nen, H.K., and Mulari, M.T.K. (2013). Novel perspectives on the transcytotic route in osteoclasts. Bonekey Rep., 2.","DOI":"10.1038\/bonekey.2013.40"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1083\/jcb.102.4.1164","article-title":"Isolated osteoclasts resorb the organic and inorganic components of bone","volume":"102","author":"Blair","year":"1986","journal-title":"J. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ar.1092240220","article-title":"Molecular mechanisms of bone resorption by the osteoclast","volume":"224","author":"Baron","year":"1989","journal-title":"Anat. Rec."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrendo.2013.137","article-title":"Osteopetrosis: Genetics, treatment and new insights into osteoclast function","volume":"9","author":"Sobacchi","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-008-9196-4","article-title":"Infantile malignant, autosomal recessive osteopetrosis: The rich and the poor","volume":"84","author":"Villa","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"ref_48","first-page":"311","article-title":"Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase\/type IV collagenase = gelatinase B) in osteoclasts: Implications for bone resorption","volume":"72","author":"Okada","year":"1995","journal-title":"Lab. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.2001.16.10.1747","article-title":"Cathepsin K, osteoclastic resorption, and osteoporosis therapy","volume":"16","author":"Zaidi","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1242\/dev.00559","article-title":"Altered fracture repair in the absence of MMP9","volume":"130","author":"Colnot","year":"2003","journal-title":"Development"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.abb.2008.01.011","article-title":"Osteoclast receptors and signaling","volume":"473","author":"Teti","year":"2008","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1084\/jem.191.2.275","article-title":"Tumor Necrosis Factor \u03b1 Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF\/RANKL-RANK Interaction","volume":"191","author":"Kobayashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-\u03b1 induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.4049\/jimmunol.169.6.3353","article-title":"IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae","volume":"169","author":"Palmqvist","year":"2002","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(02)00915-8","article-title":"Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism","volume":"32","author":"Kudo","year":"2003","journal-title":"Bone"},{"key":"ref_56","first-page":"S11","article-title":"Interleukin-6 a key mediator of systemic and local symptoms in rheumatoid arthritis","volume":"65","author":"Cronstein","year":"2007","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1074\/jbc.M706415200","article-title":"Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism","volume":"283","author":"Yao","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI112677","article-title":"Recombinant human transforming growth factor-\u03b1 stimulates the formation of osteoclast-like cells in long-term human marrow cultures","volume":"78","author":"Takahashi","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1006\/bbrc.2000.2075","article-title":"Activin A is an essential cofactor for osteoclast induction","volume":"268","author":"Fuller","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"41035","DOI":"10.1074\/jbc.M100233200","article-title":"Osteoclast-stimulating Factor Interacts with the Spinal Muscular Atrophy Gene Product to Stimulate Osteoclast Formation","volume":"276","author":"Kurihara","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4049\/jimmunol.157.2.936","article-title":"IL-10 modulates formation of osteoclasts in murine hemopoietic cultures","volume":"157","author":"Owens","year":"1996","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.4049\/jimmunol.166.8.4915","article-title":"IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro","volume":"166","author":"Horwood","year":"2001","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1073\/pnas.041493198","article-title":"IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor 1","volume":"98","author":"Bendixen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4049\/jimmunol.171.1.142","article-title":"IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-\u03baB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage","volume":"171","author":"Khapli","year":"2003","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1152\/physiol.00061.2014","article-title":"Physiological bone remodeling: Systemic regulation and growth factor involvement","volume":"31","author":"Siddiqui","year":"2016","journal-title":"Physiology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrendo.2013.179","article-title":"The role of estrogen and androgen receptors in bone health and disease","volume":"9","author":"Manolagas","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor \u03b1 and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00223-017-0365-1","article-title":"Osteomimicry: How the Seed Grows in the Soil","volume":"102","author":"Rucci","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000474904","article-title":"Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase","volume":"21","author":"Curatolo","year":"1992","journal-title":"Eur. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/(SICI)1097-0045(19990601)39:4<246::AID-PROS5>3.0.CO;2-U","article-title":"Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment","volume":"39","author":"Koeneman","year":"1999","journal-title":"Prostate"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-006-9279-8","article-title":"Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells","volume":"101","author":"Bachelier","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0022-2143(99)90201-9","article-title":"Tumor necrosis factor-\u03b1 and interleukin-1\u03b2 increase the Fas-mediated apoptosis of human osteoblasts","volume":"134","author":"Tsuboi","year":"1999","journal-title":"J. Lab. Clin. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1158\/0008-5472.CAN-15-2614","article-title":"Calcium-sensing receptor promotes breast cancer by stimulating intracrine actions of parathyroid hormone-related protein","volume":"76","author":"Kim","year":"2016","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/cncr.24896","article-title":"Pathogenesis of osteoblastic bone metastases from prostate cancer","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Guise, T.A., Mohammad, K.S., Clines, G., Stebbins, E.G., Wong, D.H., Higgins, L.S., Vessella, R., Corey, E., Padalecki, S., and Suva, L. (2006). Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res., 12.","DOI":"10.1158\/1078-0432.CCR-06-1007"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1210\/me.2006-0346","article-title":"A Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation","volume":"21","author":"Clines","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1359\/jbmr.2003.18.2.190","article-title":"Mechanisms of tumor metastasis to the bone: Challenges and opportunities","volume":"18","author":"Reddi","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"ref_79","first-page":"103","article-title":"Bone metastasis in prostate cancer: Molecular and cellular mechanisms (Review)","volume":"20","author":"Ye","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","article-title":"Integrating new discoveries into the \u201cvicious cycle\u201d paradigm of prostate to bone metastases","volume":"33","author":"Cook","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","article-title":"Recent advances in understanding the mechanism of action of bisphosphonates","volume":"6","author":"Coxon","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"Auriola","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2174\/1566524023362104","article-title":"Bisphosphonate mechanism of action","volume":"2","author":"Rodan","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00223-017-0353-5","article-title":"Bone-Targeted Therapies in Cancer-Induced Bone Disease","volume":"102","author":"Sousa","year":"2018","journal-title":"Calcif. Tissue Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcb.25266","article-title":"Risks and Benefits of Bisphosphonate Therapies","volume":"117","author":"Reyes","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.breast.2017.10.007","article-title":"Therapeutic approaches for protecting bone health in patients with breast cancer","volume":"37","author":"Niepel","year":"2018","journal-title":"Breast"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis","volume":"468","author":"Jacob","year":"2010","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-014-2955-1","article-title":"RANK expression as a prognostic and predictive marker in breast cancer","volume":"145","author":"Pfitzner","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/00365590802475904","article-title":"Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines","volume":"43","author":"Ullen","year":"2009","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ijc.24710","article-title":"Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1\u03b1\/VEGF signaling pathways in human breast cancer cells","volume":"126","author":"Tang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","article-title":"The anti-tumour effects of zoledronic acid","volume":"3","author":"Zekria","year":"2014","journal-title":"J. Bone Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev.publhealth.29.020907.090947","article-title":"The women\u2019s health initiative: Lessons learned","volume":"29","author":"Prentice","year":"2008","journal-title":"Annu. Rev. Public Health"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosphonate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials","volume":"386","author":"Coleman","year":"2015","journal-title":"Lancet"},{"key":"ref_99","first-page":"1","article-title":"Bone targeted therapies in advanced breast cancer","volume":"147","author":"Biskup","year":"2017","journal-title":"Swiss Med. Wkly."},{"key":"ref_100","first-page":"5386","article-title":"The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma","volume":"57","author":"Bilbe","year":"1997","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A Cathepsin K Inhibitor Reduces Breast Cancer Induced Osteolysis and Skeletal Tumor Burden","volume":"67","author":"Bellahcene","year":"2007","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4155\/fmc.09.4","article-title":"Future of anticathepsin K drugs: Dual therapy for skeletal disease and atherosclerosis?","volume":"1","author":"Podgorski","year":"2009","journal-title":"Future Med. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3816\/CBC.2010.n.059","article-title":"The cathepsin k inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: Results of a 4-week, double-blind, randomized, controlled trial","volume":"10","author":"Jensen","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased C-Src Expression Enhances Osteoblast Differentiation and Bone Formation","volume":"151","author":"Marzia","year":"2000","journal-title":"J. Cell Biol."},{"key":"ref_105","first-page":"5028","article-title":"C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis","volume":"63","author":"Myoui","year":"2003","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","article-title":"Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: Implications for therapy","volume":"318","author":"Rucci","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/onc.2010.73","article-title":"Src family kinase\/ABl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts","volume":"29","author":"Lee","year":"2010","journal-title":"Oncogene"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.MCT-09-0962","article-title":"SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis","volume":"9","author":"Rabbani","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1535-7163.MCT-09-1058","article-title":"Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model","volume":"9","author":"Yang","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1005","DOI":"10.1038\/cddis.2013.465","article-title":"Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification","volume":"5","author":"Maroni","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/path.4490","article-title":"Tumor but not stromal expression of \u03b23 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer","volume":"235","author":"Carter","year":"2015","journal-title":"J. Pathol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcb.21296","article-title":"Effects of Vitaxin\u00ae, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro","volume":"102","author":"Gramoun","year":"2007","journal-title":"J. Cell. Biochem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","article-title":"Tumor \u03b1v\u03b23 integrin is a therapeutic target for breast cancer bone metastases","volume":"67","author":"Zhao","year":"2007","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: From human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"ref_115","first-page":"1","article-title":"Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review","volume":"4","author":"Suen","year":"2016","journal-title":"J. Orthop. Transl."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1186\/bcr3048","article-title":"Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2\/CBF\u03b2-dependent expression of the Wnt antagonist, sclerostin","volume":"13","author":"Zeef","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00432-014-1726-z","article-title":"Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer","volume":"140","author":"Kyvernitakis","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1182\/blood.V126.23.119.119","article-title":"Anti-sclerostin treatment prevents multiple myeloma induced bone loss and reduces tumor burden","volume":"126","author":"Reagan","year":"2015","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/7\/218\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:20Z","timestamp":1760195420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/10\/7\/218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":120,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["cancers10070218"],"URL":"https:\/\/doi.org\/10.3390\/cancers10070218","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]}}}